FGF23 and hyperphosphatemia: Therefore, we conducted an exploratory evaluation of the clinical efficacy and safety of sucroferric oxyhydroxide given over a 16-week period in hemodialysis (HD) patients, and evaluated the effect on serum phosphorus levels, FGF23 levels and renal anemia treatment when HD patients receiving existing hyperphosphatemia drugs with insufficient benefit were switched to sucroferric oxyhydroxide.